ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1753

An Outcome Survey Of 40 Patients With Budd-Chiari Syndrome Due To BEHÇET’S Syndrome Followed By A Single Center

Emire Seyahi1, SerdaL Ugurlu2, Erkan Caglar3, Fatih Kantarci4, Abdullah Sonsuz5, Sebahattin Yurdakul2 and Hasan Yazici2, 1Division of Rheumatology,Department of Medicine,Cerrahpasa Medical Faculty, University of Istanbul, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 2Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 3Division of Gastroenterology, Department of Internal Medicine, Bakirkoy Research and Training Hospital, Istanbul, Turkey, 4Department of Radiology, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 5Division of Gastroenterology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome, thrombosis and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Title: Vasculitis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Budd-Chiari syndrome is a rare complication of BS with a frequency of < 1 %, and carries a high mortality rate. In a previous survey out of 14 Behcet patients with BCS, 10 (60 %) had died with a mean survival of 10 months (1). We assessed the outcome in a cohort of 40 BS patients with BCS diagnosed and followed by a single center between 1977 and 2012.

Methods: We reviewed records of about 8000 patients with BS who were registered at the multidisciplinary clinic at Cerrahpasa Medical Faculty between July 1977 and December 2012 (study closure). We identified 40 (37 M/ 3 F) patients who were diagnosed with BCS. The outcome of 40 patients was evaluated between September and December 2012. Attempts were made to contact every patient in this cohort by telephone calls or home visits. All thus contacted were called back to the outpatient clinic for a clinical evaluation, blood tests and hepatic Doppler USG. Hepatic Doppler USG specifically analyzed hepatic veins patency, intrahepatic collateral formation, caudate lobe hypertrophy, hepatomegaly, splenomegaly, and portal vein dilatation. Survival data were assessed by Kaplan-Meier analysis.

Results:  A total of 40 BS patients with BCS were surveyed. The mean age of the patients at diagnosis of BS was 28.7 ± 8.6 years, and the mean age at the onset of BCS was 30.3 ± 8.5 years. A total of 35 patients received immunosuppressive treatment (cyclophophamide n= 31; azathioprine n =4) after being diagnosed with BCS. Only 2 patients had surgical interventions. One patient had percutaneous transluminal angioplasty another transjugular intrahepatic portosystemic shunting. Fifteen patients received anticoagulant treatment. Apart from this, 3 patients were treated with thrombolytic treatment which was ineffective. Additionally, 17 patients received diuretics. By the end of the study, we had the outcome information in all patients: 20 patients (19 M/1F) (50 %) had died, while the remaining 20 were alive. Of these, 17 could be re-evaluated in the clinic. Among the patients who had died, the median survival time was 8 months (IQR: 4- 54 months). The causes of mortality were mainly due to hepatic failure (n =17) (85 %). Additionally, one had died due to myocardial infarction, another due to suicide and another with unknown cause. Postmortem study was available in one patient. Mortality rate among patients diagnosed between 1977-2000 (10/15, 67 %) was somewhat higher (Log rank P= 0.75). compared to those diagnosed between 2001-2012 (10/25, 40 %), however, the difference did not reach statistical significance in the survival analysis. Final hepatic USG among 17 patients who survived showed occlusion in one ore more hepatic veins in 12, caudate lobe hypertrophy in 8, splenomegaly in 3, and portal vein dilatation in 3. It was noted that all 17 patients had multiple intrahepatic veno-venous collaterals with good drainage.

Conclusion:

BCS due to BS still caries serious mortality. Mortality rate perhaps tend to decrease after 2000. Formation of intrahepatic veno-venous collaterals seem to be the only factor important in the survival.

References: Reference:

1)      Bayraktar Y, et al. Budd-Chiari syndrome: a common complication of Behçet’s disease. Am J Gastroenterol. 1997;92:858-62.


Disclosure:

E. Seyahi,
None;

S. Ugurlu,
None;

E. Caglar,
None;

F. Kantarci,
None;

A. Sonsuz,
None;

S. Yurdakul,
None;

H. Yazici,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-outcome-survey-of-40-patients-with-budd-chiari-syndrome-due-to-behcets-syndrome-followed-by-a-single-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology